182 related articles for article (PubMed ID: 23145146)
1. Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.
Luise C; Merolla F; Leone V; Paladino S; Sarnataro D; Fusco A; Celetti A
PLoS One; 2012; 7(11):e49298. PubMed ID: 23145146
[TBL] [Abstract][Full Text] [Related]
2. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
[TBL] [Abstract][Full Text] [Related]
3. CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1.
Leone V; Mansueto G; Pierantoni GM; Tornincasa M; Merolla F; Cerrato A; Santoro M; Grieco M; Scaloni A; Celetti A; Fusco A
Oncogene; 2010 Jul; 29(30):4341-51. PubMed ID: 20498639
[TBL] [Abstract][Full Text] [Related]
4. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.
Merolla F; Luise C; Muller MT; Pacelli R; Fusco A; Celetti A
PLoS One; 2012; 7(5):e36177. PubMed ID: 22655027
[TBL] [Abstract][Full Text] [Related]
5. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
Laxmi A; Gupta P; Gupta J
Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
[TBL] [Abstract][Full Text] [Related]
6. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
7. An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.
Zhang T; Lu Y; Ye Q; Zhang M; Zheng L; Yin X; Gavine P; Sun Z; Ji Q; Zhu G; Su X
Genes Chromosomes Cancer; 2015 Mar; 54(3):168-76. PubMed ID: 25407564
[TBL] [Abstract][Full Text] [Related]
8. A novel RET/PTC variant detected in a pediatric patient with papillary thyroid cancer without ionization history.
Halkova T; Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Sykorova P; Vlcek P; Reboun M; Katra R; Kodetova D; Schrumpf M; van Wezel T; Morreau H; Bendlova B
Hum Pathol; 2015 Dec; 46(12):1962-9. PubMed ID: 26472164
[TBL] [Abstract][Full Text] [Related]
9. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.
Staubitz JI; Musholt TJ; Schad A; Springer E; Lang H; Rajalingam K; Roth W; Hartmann N
Cancer Genet; 2019 Oct; 238():10-17. PubMed ID: 31425920
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6.
Jia M; Shi Y; Li Z; Lu X; Wang J
Cancer Lett; 2019 Feb; 443():145-156. PubMed ID: 30503553
[TBL] [Abstract][Full Text] [Related]
11. CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells.
De Falco V; Tamburrino A; Ventre S; Castellone MD; Malek M; Manié SN; Santoro M
Cancer Res; 2012 Mar; 72(6):1449-58. PubMed ID: 22271686
[TBL] [Abstract][Full Text] [Related]
12. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
Kumarasamy VM; Shin YJ; White J; Sun D
BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
[TBL] [Abstract][Full Text] [Related]
13. A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.
Cantisani MC; Parascandolo A; Perälä M; Allocca C; Fey V; Sahlberg N; Merolla F; Basolo F; Laukkanen MO; Kallioniemi OP; Santoro M; Castellone MD
Oncotarget; 2016 May; 7(19):28510-22. PubMed ID: 27058903
[TBL] [Abstract][Full Text] [Related]
14. Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species.
Zeindl-Eberhart E; Liebmann S; Jungblut PR; Mattow J; Schmid M; Kerler R; Rabes HM
Amino Acids; 2011 Jul; 41(2):415-25. PubMed ID: 20839015
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
16. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
[TBL] [Abstract][Full Text] [Related]
17. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
Kim YR; Byun HS; Won M; Park KA; Kim JM; Choi BL; Lee H; Hong JH; Park J; Seok JH; Kim DW; Shong M; Park SK; Hur GM
BMC Cancer; 2008 May; 8():144. PubMed ID: 18498667
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells.
Xing S; Furminger TL; Tong Q; Jhiang SM
J Biol Chem; 1998 Feb; 273(9):4909-14. PubMed ID: 9478934
[TBL] [Abstract][Full Text] [Related]
19. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.
Gandhi M; Dillon LW; Pramanik S; Nikiforov YE; Wang YH
Oncogene; 2010 Apr; 29(15):2272-80. PubMed ID: 20101222
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]